<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/852A7926-9597-4E82-9326-155436547A0C"><gtr:id>852A7926-9597-4E82-9326-155436547A0C</gtr:id><gtr:name>PharmAccess Foundation</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/852A7926-9597-4E82-9326-155436547A0C"><gtr:id>852A7926-9597-4E82-9326-155436547A0C</gtr:id><gtr:name>PharmAccess Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5CCB64D5-FCBB-4CC6-B9E4-F3D4B42E53BB"><gtr:id>5CCB64D5-FCBB-4CC6-B9E4-F3D4B42E53BB</gtr:id><gtr:firstName>Deenan</gtr:firstName><gtr:surname>Pillay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5"><gtr:id>B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5</gtr:id><gtr:firstName>Pontiano</gtr:firstName><gtr:surname>Kaleebu</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U950080938"><gtr:id>274E17B8-AB0C-430B-966F-44C0D7579B40</gtr:id><gtr:title>Basic Science Programme / Research on ART resistance</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U950080938</gtr:grantReference><gtr:abstractText>In the past few years there has been an increase in access to anti-retroviral therapy (ART) of HIV infection in resource limited settings. Studies are also underway to find the most cost effective approaches to deliver ART to different populations in such settings. One of the major challenges of delivery of ART is the development of drug resistance. MRC/UVRI is therefore conducting different studies to investigate the development of resistance under the different delivery settings in our population infected with HIV subtypes A and D. We also participate in national activities aimed at prevention, monitoring and surveillance of HIV drug resistance. These include surveillance of drug resistance in recently infected individuals and in those on treatment in research projects and public HIV care programmes. All these efforts will contribute to better understanding of how resistance develops and how we can prevent it. Methods to test for drug resistance involve extracting the viral genetic materials from patient blood participating in a number of cohorts that we support and performing a number of laboratory experiments including sequencing using different machines to detect the genetic sequences combined with a number of mathematical analyses.</gtr:abstractText><gtr:technicalSummary>Overall aim: To provide information on the nature and frequency of ART resistant mutants occuring in rural and urban setting under various ART delivery routes. Specific objectives: 1) To describe ART resistance in COLTART and DART participants 2) To describe ART resistance among recently infected individuals 3) To participate in national ART prevention and monitoring activities including hosting the National ART drug resistance reference laboratory 4) Introduction of the use of DBS in drug resistance monitoring
Background: There are efforts to study the most cost effective modes of ART delivery in resource limited settings such as the recently concluded Dart trial. Understanding the effect of these approaches on viral suppression and ART drug resistance in these communities infected with HIV subtypes A,C and D is of importance. In addition, as a contribution to the prevention and monitoring of ART drug resistance, we are participating in a number of studies including looking at the frequency of resistant viruses in recently infected individuals and those on treatment. We also host the national HIV drug resistance reference laboratory. 
Laboratory methods: Viral loads are measured by Roche Amplicor v1.5 assay for baseline samples (lower limit of detection 400 copies/ml), and the Roche ultra-sensitive assay for other samples (lower limit of detection 50 copies/ml). Viral RNA is extracted from cryo-preserved serum using QIAamp Viral RNA Mini Kit. Reverse transcription and first round PCR is done using QIAGEN OneStep RT-PCR Kit and subsequent sequencing of a consensus contiguous region of the pol gene by an in-house sequencing method, using a Beckman capillary sequencer or an ABI capillary sequencer. Mutations at baseline are identified by reference to the WHO consensus list for surveillance of transmitted drug resistance and mutations at later time points by reference to the most recent IAS-USA classification. Subtype was inferred from the pol sequences using the REGA HIV subtyping algorithm. We are also introducing the use of DBS in drug resistance
Public health application: Better understanding of the effectiveness of the different ART delivery approaches and prevention of HIV drug resistance development.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2428047</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>PharmAccess Foundation</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>HIV Drug resistance surveillance</gtr:description><gtr:id>9B07B0D9-EB96-4925-AE13-AA444908A21F</gtr:id><gtr:impact>Information of transmitted HIV drug resistance and publications</gtr:impact><gtr:outcomeId>9FF623FECB6-1</gtr:outcomeId><gtr:partnerContribution>Training and network</gtr:partnerContribution><gtr:piContribution>We have conducted molecular virology experiments</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dart virology substudies</gtr:description><gtr:id>94F6BB0B-3393-4F4D-B807-DA7956066467</gtr:id><gtr:impact>Training, other capacity building and publications</gtr:impact><gtr:outcomeId>C6F285B65CD-1</gtr:outcomeId><gtr:partnerContribution>Training of staff and in publications</gtr:partnerContribution><gtr:piContribution>We have provided sequence data, participated in the presentation of data and publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Joint Clinical Research Center, Kampala</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Dart viral load</gtr:description><gtr:id>235E549F-BDB7-4106-A156-18869AAB5738</gtr:id><gtr:impact>Viral load testing, publications and sharing of information</gtr:impact><gtr:outcomeId>1B4041F5C49-1</gtr:outcomeId><gtr:partnerContribution>Viral load testing and publications</gtr:partnerContribution><gtr:piContribution>Viral load testing and publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>Dart Drug resistance</gtr:description><gtr:id>B6D34839-9DD2-43D0-B5DF-21804EE9D6D5</gtr:id><gtr:impact>Publications and abstracts</gtr:impact><gtr:outcomeId>695CD67CAFF-1</gtr:outcomeId><gtr:partnerContribution>Analysis of Data and publications</gtr:partnerContribution><gtr:piContribution>Analysis of Data and publications</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Ministry of Health</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>CE9F4973-00C5-4488-9986-AF75EE680695</gtr:id><gtr:impact>We have presented information on the development of drug resistance to the Ministry of Health officials

In the context of Dart the ministry of health is aware of the efficacy of the drug regimens The ministry is aware of the prevalence of mutations in drug naice patients and in recently infected people</gtr:impact><gtr:outcomeId>EC4FC6393B9</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Surveillance of HIV drug resistance</gtr:description><gtr:end>2010-05-02</gtr:end><gtr:fundingOrg>PharmAccess Foundation</gtr:fundingOrg><gtr:id>19302C72-7A98-4A00-AFB3-C979A2C90DD6</gtr:id><gtr:outcomeId>6D99E9CB3D20</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>291543</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Efficacy and drug resistance development in patients on tripe Nucleosides</gtr:description><gtr:end>2009-02-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>DF9406D8-146B-460A-BAA6-2415858086E2</gtr:id><gtr:outcomeId>DB74E2AF3C00</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2006-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (The emergence and impact of HIV resistance associated mutations under the public health approach to ART: Implications for resource limited countries)</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>737DC396-F83C-41A1-95FE-3EB15F0E08F0</gtr:id><gtr:outcomeId>9427DF2BCD20</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Relevance of virological monitoring in patient management</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>544DD075-AAF6-4C0A-B0DD-D0D8A3A76244</gtr:id><gtr:impact>Currently we show no differences in drug resistance development in the different HIV subtypes we have Laboratory monitoring only can lead to good virological response though there is more resistance development in patients who continue on drugs when there is virological failure</gtr:impact><gtr:outcomeId>CB01A5175C8</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E1E7CDC8-EE8A-49D4-BE83-3E2401007E47</gtr:id><gtr:title>The arrival of untreatable multidrug-resistant HIV-1 in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e86b0b99ea34cdc07671dabdf5718729"><gtr:id>e86b0b99ea34cdc07671dabdf5718729</gtr:id><gtr:otherNames>Magambo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>546482e8e94357.70261621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>409BCC97-AC39-4735-BA6D-F27B58DB58B9</gtr:id><gtr:title>HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81c9002da10f10505970d2a34a5541d1"><gtr:id>81c9002da10f10505970d2a34a5541d1</gtr:id><gtr:otherNames>Hamers RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>cnUmjD8KQsz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C0D3EE2-0B7D-4D9F-BBF7-CE4AA6C71E94</gtr:id><gtr:title>An appraisal of indicators used to monitor the treated population in antiretroviral programmes in low-income countries.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50e56361c032477c2f55b7b6038aa672"><gtr:id>50e56361c032477c2f55b7b6038aa672</gtr:id><gtr:otherNames>Hoskins S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>fLxU1pQfEMF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECC137D4-7FCF-415C-9466-23B7F71E57A1</gtr:id><gtr:title>The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9859179eab8d2f5d7df659dae68e5864"><gtr:id>9859179eab8d2f5d7df659dae68e5864</gtr:id><gtr:otherNames>Dolling DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>58c6a803afecb0.35457036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A17F172-CC3A-4DD2-AA14-F62ACAB95C97</gtr:id><gtr:title>Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a115fb22ae8b5eb1d761afe50087d24"><gtr:id>9a115fb22ae8b5eb1d761afe50087d24</gtr:id><gtr:otherNames>McCormick AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>Qwi7a4bbbBj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D7CCC8A-947C-45D1-A15E-D8FCCFBD9702</gtr:id><gtr:title>Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/240e481ef0597cb94a0384928615c218"><gtr:id>240e481ef0597cb94a0384928615c218</gtr:id><gtr:otherNames>Dunn DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>MrE9ty2e6gN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>029093B3-A012-43C2-AE15-DFFBB7803E6E</gtr:id><gtr:title>Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46f2d9ffe46edb4c77cc56e89bb86f5"><gtr:id>c46f2d9ffe46edb4c77cc56e89bb86f5</gtr:id><gtr:otherNames>TenoRes Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58c6a804900760.65827367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E345C14-8519-4A4D-ACC7-80D32669FD86</gtr:id><gtr:title>HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1468a3c79a930345b1162a38bc32d1aa"><gtr:id>1468a3c79a930345b1162a38bc32d1aa</gtr:id><gtr:otherNames>Gupta RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5aa914e0bb7259.59799418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9719DA72-3EC3-4363-8732-96E313EC4D24</gtr:id><gtr:title>Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b2740857e0a6a774e56992f6a12381e"><gtr:id>7b2740857e0a6a774e56992f6a12381e</gtr:id><gtr:otherNames>Schmidt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>546482ead4cda3.17976774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39B7F9CF-1A64-44A2-8C97-647A27E51738</gtr:id><gtr:title>Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3417d4ce8ff7e6e00ba6e34e64293c2b"><gtr:id>3417d4ce8ff7e6e00ba6e34e64293c2b</gtr:id><gtr:otherNames>DART Virology Group and Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>F24973449EC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C48DA004-C554-4890-8B22-3B6662CC16A7</gtr:id><gtr:title>Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3351d89d5f121bef6fc5cb4126499a9b"><gtr:id>3351d89d5f121bef6fc5cb4126499a9b</gtr:id><gtr:otherNames>Goodall RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58c6a803e6eb52.30301979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A9CDAE5-54D6-48CB-82B5-900AA95B4C79</gtr:id><gtr:title>Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c854aab3bcd1183105431f6d22f637c4"><gtr:id>c854aab3bcd1183105431f6d22f637c4</gtr:id><gtr:otherNames>Price MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>hdj3TAiXc9R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA109B0A-8C55-494D-89E3-6692B6D6D3AE</gtr:id><gtr:title>Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05192395343504676076a1c822caa40c"><gtr:id>05192395343504676076a1c822caa40c</gtr:id><gtr:otherNames>Wallis CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>69D5D1677CD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>343DEA21-EA1D-4A51-996F-1FAB5C7F332B</gtr:id><gtr:title>Short communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naive individuals from Ugandan fishing communities of Lake Victoria.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39f4d07cf6ffe1db543fb6add451a228"><gtr:id>39f4d07cf6ffe1db543fb6add451a228</gtr:id><gtr:otherNames>Nazziwa J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>pm_14935_25_23173702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FAC37B3-FFBB-4B7E-9368-A51DD6F79816</gtr:id><gtr:title>Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a36c594481c9e5162bca5d1edaf25ac0"><gtr:id>a36c594481c9e5162bca5d1edaf25ac0</gtr:id><gtr:otherNames>Kityo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>siGZckjPWCD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7282E400-1D16-4FBC-AE47-6875F730056D</gtr:id><gtr:title>Field study of dried blood spot specimens for HIV-1 drug resistance genotyping.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2046d415c257b2fe0d1ecb7aa072c4d1"><gtr:id>2046d415c257b2fe0d1ecb7aa072c4d1</gtr:id><gtr:otherNames>Parry CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>546482e96e1603.28390315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44A5FFCB-78B1-40C1-9E57-931CD38EEBFC</gtr:id><gtr:title>Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3351d89d5f121bef6fc5cb4126499a9b"><gtr:id>3351d89d5f121bef6fc5cb4126499a9b</gtr:id><gtr:otherNames>Goodall RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>546482ea17df73.20392603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15FF6759-C2B7-4E6C-9674-CA817D04BF39</gtr:id><gtr:title>Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a8bde31d95ec586098b2322368ff463"><gtr:id>5a8bde31d95ec586098b2322368ff463</gtr:id><gtr:otherNames>Ndembi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>dX3jZ2FuNwQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>981A7F61-CB90-45EC-9ADF-8E2AA2E83535</gtr:id><gtr:title>Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546482eb777b39.32575740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F52A216B-08E9-4DAC-BCAE-A54E2290946B</gtr:id><gtr:title>Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7da11026bd77b80de9adabc4b8b7c17f"><gtr:id>7da11026bd77b80de9adabc4b8b7c17f</gtr:id><gtr:otherNames>Sutherland KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56deb2e753a515.12112407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EE7013A-A840-4DE6-B100-7F02C4BD3982</gtr:id><gtr:title>Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209dc6a04f521377c3617f5457c4355c"><gtr:id>209dc6a04f521377c3617f5457c4355c</gtr:id><gtr:otherNames>Munderi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>Jy71zJfpxUM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD8DB3EF-6163-46E7-B966-2018A14368E4</gtr:id><gtr:title>Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbce9c13cd50bb743310539932d68ca3"><gtr:id>cbce9c13cd50bb743310539932d68ca3</gtr:id><gtr:otherNames>Baalwa J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>pm_14935_25_23123038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60DBE0F6-7D42-4B97-AB71-474779D4398D</gtr:id><gtr:title>Low drug resistance levels among drug-naive individuals with recent HIV type 1 infection in a rural clinical cohort in southwestern Uganda.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d65a9eea965e9c3dad2ff04c4f72830d"><gtr:id>d65a9eea965e9c3dad2ff04c4f72830d</gtr:id><gtr:otherNames>Ssemwanga D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>pm_14935_25_22616647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42391BBC-F366-47FF-9342-27FC18FADD1D</gtr:id><gtr:title>Human Immunodeficiency Virus (HIV) Drug Resistance in African Infants and Young Children Newly Diagnosed With HIV: A Multicountry Analysis.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfd08c68f24d26d290786ef880213ad0"><gtr:id>bfd08c68f24d26d290786ef880213ad0</gtr:id><gtr:otherNames>Jordan MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5aa914e0ece6b7.01961565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABD06662-D81A-4358-AFBD-D90760365B4C</gtr:id><gtr:title>High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a36c594481c9e5162bca5d1edaf25ac0"><gtr:id>a36c594481c9e5162bca5d1edaf25ac0</gtr:id><gtr:otherNames>Kityo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546482ea3b1270.92431524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FAD2106-7130-4279-A156-5A5BB6B1C9E5</gtr:id><gtr:title>Personal barriers to antiretroviral therapy adherence: case studies from a rural Uganda prospective clinical cohort.</gtr:title><gtr:parentPublicationTitle>African health sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fd39f3f7dc2967ed12398c5352b29e"><gtr:id>03fd39f3f7dc2967ed12398c5352b29e</gtr:id><gtr:otherNames>Mayanja BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1680-6905</gtr:issn><gtr:outcomeId>546482eb522599.70130463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E617B28-22E8-436B-BC54-97B1ECA2B328</gtr:id><gtr:title>Genotypic variation in the pol gene of HIV type 1 in an antiretroviral treatment-naive population in rural southwestern Uganda.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ff03e84ab92ca9cedd615e922633e2"><gtr:id>93ff03e84ab92ca9cedd615e922633e2</gtr:id><gtr:otherNames>Gale CV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>54B2DC3981F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2AA9939-7730-42F8-818A-D6500F4ED25D</gtr:id><gtr:title>Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a115fb22ae8b5eb1d761afe50087d24"><gtr:id>9a115fb22ae8b5eb1d761afe50087d24</gtr:id><gtr:otherNames>McCormick AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>ESvR6fUpGpw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A252D770-9582-40FD-8374-F4652D047ABC</gtr:id><gtr:title>Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d410d465dc7e420939068f2d6c672c01"><gtr:id>d410d465dc7e420939068f2d6c672c01</gtr:id><gtr:otherNames>Kaleebu P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56deb2e64443b4.09172645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F93168A-A25A-4854-B78A-E049358F5977</gtr:id><gtr:title>Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/051cf62d6d905f0304eb0c4d1af8ba2e"><gtr:id>051cf62d6d905f0304eb0c4d1af8ba2e</gtr:id><gtr:otherNames>Lyagoba F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>Ezt7UCmchYf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CB06D14-8307-4DBF-B6B7-5DDB80504374</gtr:id><gtr:title>From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a812e4f1abe545f9b5ed7c881ce39f76"><gtr:id>a812e4f1abe545f9b5ed7c881ce39f76</gtr:id><gtr:otherNames>Namakoola I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>58c6a8042f7754.06585091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24283909-FA6C-41E9-9114-0ED3E4296514</gtr:id><gtr:title>Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09843440e2f526123c605f0f6c9bc916"><gtr:id>09843440e2f526123c605f0f6c9bc916</gtr:id><gtr:otherNames>Gregson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58c6a80463a338.99959797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD726EE6-2AF2-4414-8BA5-BF35C76AF643</gtr:id><gtr:title>Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a8bde31d95ec586098b2322368ff463"><gtr:id>5a8bde31d95ec586098b2322368ff463</gtr:id><gtr:otherNames>Ndembi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>D7DE789534B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A61C8B51-4B17-4EED-AAF6-4AAEE7D03B01</gtr:id><gtr:title>Transmitted antiretroviral drug resistance among drug-naive female sex workers with recent infection in Kampala, Uganda.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d65a9eea965e9c3dad2ff04c4f72830d"><gtr:id>d65a9eea965e9c3dad2ff04c4f72830d</gtr:id><gtr:otherNames>Ssemwanga D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_14935_25_22544200</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U950080938</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>